- Home
- DHF vs AMRN Comparison
DHF vs AMRN Comparison
Compare DHF & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$13.71
Company Overview
Basic Information| Metric | DHF | AMRN |
|---|---|---|
| Founded | 1998 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.7M | 339.8M |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | DHF | AMRN |
|---|---|---|
| Price | $2.49 | $13.71 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 451.1K | 94.8K |
| Earning Date | 01-01-0001 | 10-29-2025 |
| Dividend Yield | ★ 7.65% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $226,733,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.06 | $7.08 |
| 52 Week High | $2.39 | $20.90 |
Technical Indicators
Market Signals| Indicator | DHF | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 45.97 | 39.25 |
| Support Level | $2.46 | $13.48 |
| Resistance Level | $2.49 | $14.49 |
| Average True Range (ATR) | 0.03 | 0.64 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 41.67 | 24.66 |
Price Performance
Historical Comparison DHF
AMRN
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.